Glycart Biotechnology AG
Glycart Biotechnlogy is a biopahramceutical company that develops and commercializes a new generation of antibodies based on its proprietary GlycoMAbTM technology. The company was acquired in 2005 by F. Hoffmann-La Roche AG for CHF 235 million.
